Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 4/20 | 0.38 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | PPARA | Q07869 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | PPARD | Q03181 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13851993 | 0.86 | HPGD (0.41) | CA12CA1CA2CA9LMNA | |
| SCHEMBL13851994 | 0.83 | SCN9A (0.37) | S1PR1MAPTSMN1; SMN2KDM4E | |
| SCHEMBL16140751 | 0.78 | S1PR1 (0.44) | S1PR1S1PR5PPARAPPARDKDM4E | |
| SCHEMBL79439 | 0.78 | S1PR1 (0.47) | S1PR1S1PR5PPARALMNAMAPT | |
| SCHEMBL2469794 | 0.74 | PKM (0.47) | S1PR1S1PR5MAPTKDM4E | |
| SCHEMBL13851996 | 0.71 | TAS1R3 (0.40) | MAPT | |
| SCHEMBL2469798 | 0.69 | S1PR1 (0.37) | S1PR1S1PR5PPARAPPARD | |
| SCHEMBL3493151 | 0.69 | S1PR1 (0.59) | S1PR1S1PR5PPARAPPARD | |
| SCHEMBL86294 | 0.68 | S1PR1 (0.50) | S1PR1S1PR5LMNAKDM4E | |
| SCHEMBL31435356 | 0.68 | S1PR1 (0.58) | S1PR1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137530-A1 | Amine Compound and Use Thereof for Medical Purposes | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137530-A1 | Amine Compound and Use Thereof for Medical Purposes | HRH3, HRH2, HRH4 | S1PR1 370/4885S1PR5 463/4885CA12 540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.